Advertisement

Topics

Celltrion and Teva set to take lead in US rituximab biosimilars

07:37 EDT 3 Jul 2017 | pharmaphorum

Celltrion and Teva look set to get a biosimilar of Roche’s blockbuster MabThera/Rituxan (rituximab) onto the US market ahead of rivals. Rituximab went off patent in the US last year, leaving it open to competition from cheaper biosimilar vers...

Original Article: Celltrion and Teva set to take lead in US rituximab biosimilars

NEXT ARTICLE

More From BioPortfolio on "Celltrion and Teva set to take lead in US rituximab biosimilars"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...

Biosimilars
Biosimilars or Follow-on biologics are terms used to describe officially approved subsequent versions of innovator biopharmaceutical products made by a different sponsor following patent and exclusivity expiry on the innovator product. Products that ar...

Biotechnology Business
Alliances Astrazeneca Bioethics Boehringer Clinical Research Organization Collaborations GSK Johnson & Johnson Lilly Merck Mergers and Acquisitions Nexium Novartis Pfizer Roche Sanofi ...